H&T Group is calling time on its 19-year tenure as a fixture on London’s AIM market after agreeing a £297million…
Alzheimer’s disease costs the global economy $1.3trillion a year. That is the estimate from the Alzheimer’s Society, reflecting the growing…
You’ll be hearing a lot about this next week. On 19 June, AIM marks its 30th anniversary.Expect a flurry of…
Raising fresh capital is a familiar rhythm for early-stage biotech companies. For Poolbeg Pharma, the question is not simply whether it can…
Are the green shoots starting to emerge for the junior market? Well, it certainly seems to be the case with…
By IAN LYALL AT PROACTIVE INVESTORS FOR THISISMONEY.CO.UK Updated: 13:27, 10 March 2025 A 42 per cent profit. That’s what…
Electric vehicles are constantly improving, but there’s no doubt these ever-evolving petrol and diesel alternatives still face scrutiny from consumers.Whether…
For ambitious junior life sciences companies, often the ultimate goal is securing partnerships with well-funded industry players to propel drug…
Kromek Group left investors cheering this week as it unmasked a road to profitability via a deal with Siemens Healthineers.Shares…
Britain is no longer the industrial powerhouse it once was, having ceded its dominance in manufacturing to the US, Germany,…